Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06623162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Study acronym: SASAN-SPARING
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based On Clinical Response To Neoadjuvant Treatment In Molecularly Categorized Muscle Invasive Bladder Cancer Patients
Trial Details
NCT Number NCT06623162
Lead Sponsor Fundación de investigación HM
Collaborators: MFAR Clinical Research S.L., Hospital Universitario 12 de Octubre
Conditions
(from sponsor)		 Mibc, Muscle Invasive Bladder Cancer
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov